NCT03050411

Apatinib Combine With EGFR-TKI for Advanced EGFR-TKI-resistant Non-Small Cell Lung Cancer

A Study of Apatinib Combine With EGFR-TKI for Advanced EGFR-TKI-resistant Non-Small Cell Lung Cancer

• Status: Unknown
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 30 (estimated)
• Sponsor: Peking University Third Hospital · Academic / Other
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs), including gefitinib demonstrate excellent effect on the treatment of non-small cell lung cancer (NSCLC) patients with EGFR mutations. However, patients who are initially sensitive to the drugs eventually become resistance. Apatinib is a highly selective VEGFR2 inhibitor and reduces the angiogenesis of tumor efficiently. In this study, the investigators aim to explore the efficacy and reasonable dosage of apatinib combining with EGFR-TKI in advanced non-squamous non-small cell lung cancer with EGFR-TKI resistance.

Detailed description

Primary Outcome Measure: efficacy and reasonable dosage of the combination of apatinib and EGFR-TKI in advanced non-squamous non-small cell lung cancer with EGFR-TKI resistance. Secondary Outcome Measures: Progression free survival, overall survival, Side effects.

Conditions

• Nonsmall Cell Lung Cancer

Interventions

Type	Name	Description
DRUG	Apatinib Mesylate Tablets	250mg, 500mg, 750mg, q.d., p.o.
DRUG	EGFR-TKIs (Erlotinib, Gefitinib and Osimertinib)	EGFR-TKIs include but are not limited erlotinib, gefitinib and osimertinib

Timeline

• Start date: 2016-05-01
• Primary completion: 2019-06-01
• Completion: 2019-10-01
• First posted: 2017-02-10
• Last updated: 2017-02-10

Locations

1 site across 1 country: China